Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme

Neuro-Oncology

Volumn 15, Issue 10, 2013, Pages 1366-1378

  El Hindy, Nicolai ^a   Keyvani, Kathy ^a   Pagenstecher, Axel ^b   Dammann, Philip ^a   Sandalcioglu, I Erol ^a   Sure, Ulrich ^a   Zhu, Yuan ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Dll4 Notch signaling; macrophage microglia; microvascular density; primary glioblastoma multiforme; vascular pattern

Indexed keywords

LAMININ; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NOTCH RECEPTOR; NOTCH4 RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASTROCYTE; CELLS; CLINICAL ARTICLE; EDEMA; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MALE; METHYLATION; MICROGLIA; NEOPLASM; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

DLL4-NOTCH SIGNALING; MACROPHAGE/MICROGLIA; MICROVASCULAR DENSITY; PRIMARY GLIOBLASTOMA MULTIFORME; VASCULAR PATTERN;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL PROLIFERATION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84885011140     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not071     Document Type: Article

References (71)

1. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215-225; discussion 226-219. (Pubitemid 34212595)
2. Sant M, van der Sanden G, Capocaccia R. Survival rates for primary malignant brain tumours in Europe. Eur J Cancer. 1998;34(14):2241-2247. (Pubitemid 29036893)
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892-6899. (Pubitemid 39330996)
4. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108. (Pubitemid 40287792)
5. DemuthT, BerensME.Molecularmechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70(2):217-228. (Pubitemid 39545733)
6. RothW,Wagenknecht B, Klumpp A, et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. 2001;8(4):403-410. (Pubitemid 32409611)
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
8. Artavanis-Tsakonas S, RandMD, Lake RJ. Notch signaling: cell fate control and signal integrationin development. Science. 1999;284(5415):770-776. (Pubitemid 29291335)
9. Gray GE,MannRS, Mitsiadis E, et al.Humanligands of theNotch receptor. Am J Pathol. 1999;154(3):785-794.
10. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol. 2003;23(4):543-553. (Pubitemid 36438065)
11. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194(3):237-255. (Pubitemid 36176887)
12. Shutter JR, Scully S, FanW, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000;14(11):1313-1318. (Pubitemid 30397075)
13. Regan JN, MajeskyMW. Building a vessel wall with notch signaling. Circ Res. 2009;104(4):419-421.
14. Jang MS, Zlobin A, KastWM,Miele L. Notch signaling as a target in multimodality cancer therapy. Curr Opin Mol Ther. 2000;2(1):55-65. (Pubitemid 30140204)
15. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev. 2007;28(3):339-363. (Pubitemid 46984831)
16. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007;64(21):2746-2762. (Pubitemid 351152259)
17. Gutierrez A, Look AT. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell. 2007;12(5):411-413. (Pubitemid 350046412)
18. Fitzgerald K, Harrington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene. 2000;19(37):4191-4198.
19. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res. 2008;14(17):5314-5317.
20. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle. 2008;7(8): 965-970. (Pubitemid 351679827)
21. Zhang X, Chen T, Zhang J, et al. Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Sci. 2012;103(2):181-190.
22. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007;7(5):327-331. (Pubitemid 46652486)
23. StockhausenMT, Kristoffersen K, Poulsen HS.The functional role of Notch signaling in human gliomas. Neuro Oncol 2010 12 (2) 199-211.
24. Poellinger L, LendahlU. Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr Opin Genet Dev. 2008;18(5): 449-454. (Pubitemid 50260912)
25. Li JL, Sainson RC, ShiW, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67(23):11244-11253. (Pubitemid 350248550)
26. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 2001;69(2-3): 135-144. (Pubitemid 33755062)
27. Kuhnert F, Kirshner JR, Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell. 2011;3(1):20.
28. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353-2363. (Pubitemid 40490146)
29. Kanamori M, Kawaguchi T, Nigro JM, et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007;106(3):417-427. (Pubitemid 46354295)
30. Jubb AM, Browning L, Campo L, et al. Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma. Histopathology. 2012;60(5):740-747.
31. Gursel DB, Berry N, Boockvar JA. The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery. 2012;70(2):N19-N21.
32. Gaetani P, Hulleman E, Levi D, et al. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori. 2010;96(1):97-102.
33. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27(1):65-73. (Pubitemid 26052641)
34. Stark AM, van de Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg. 2012;114(7):840-845.
35. Takai D, Yagi Y, Wakazono K, et al. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylationsensitive representational difference analysis. Oncogene. 2001;20(51): 7505-7513. (Pubitemid 33086910)
36. MollemannM,Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of theMGMTgene in oligodendroglial tumors. Int J Cancer. 2005;113(3):379-385. (Pubitemid 40038704)
37. Schaich M, Kestel L, Pfirrmann M, et al. AMDR1(ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009;20(1):175-181.
38. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108. (Pubitemid 351818697)
39. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36(2):169-180.
40. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
41. Onguru O, Gamsizkan M, Ulutin C, Gunhan O. Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma. Neuropathology. 2008;28(1):29-34.
42. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003;13(2):133-143. (Pubitemid 36460814)
43. Preusser M, Birner P, Hainfellner JA. Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens. Clin Neuropathol. 2004;23(5):238-240. (Pubitemid 39222715)
44. Jubb AM, Soilleux EJ, Turley H, et al. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 2010;176(4):2019-2028.
45. Jubb AM, Turley H, Moeller HC, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009;101(10):1749- 1757.
46. Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res. 2006;12(16):4836-4844. (Pubitemid 44338568)
47. Chen J, Kesari S, Rooney C, et al. Inhibition of Notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer. 2010;1(8):822-835.
48. Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol. 2012;38(2):201-212.
49. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14(4):391-396. (Pubitemid 30131884)
50. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032-1037. (Pubitemid 46018516)
51. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005;65(19):8690- 8697. (Pubitemid 41377356)
52. Li JL, Sainson RC, Oon CE, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71(18):6073-6083.
53. Ding XY, Ding J, Wu K, et al. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth. Oncogene. 2012;31(23):2899-2906.
54. Wong GW, Knowles GC, Mak TW, Ferrando AA, Zuniga-Pflucker JC. HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRbeta-selected mouse thymocytes. Blood. 2012;120(7):1439-1448.
55. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008;20(6):652-661.
56. Norden AD, Drappatz J,Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009;5(11):610-620.
57. Preusser M, Heinzl H, Gelpi E, et al. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer. 2006;107(1):162-170. (Pubitemid 43939043)
58. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about antiangiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009;9:444.
59. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444(7122):1083-1087. (Pubitemid 46018529)
60. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996;92(3):288-293. (Pubitemid 26278960)
61. Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia. 2011;59(3):472-485.
62. Demuth T, Rennert JL, Hoelzinger DB, et al. Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines. BMC Genomics. 2008;9:54.
63. AltermanRL, Stanley ER. Colony stimulating factor-1 expression inhuman glioma. Mol Chem Neuropathol. 1994;21(2-3):177-188. (Pubitemid 24174521)
64. Wang Z, Li Y, Banerjee S, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem. 2010;109(4):726-736.
65. Sure U, Ruedi D, Tachibana O, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol. 1997;56(7): 782-789. (Pubitemid 27280188)
66. Frenel JS, Botti M, Loussouarn D, Campone M. [Prognostic and predictive factors for gliomas in adults]. Bull Cancer. 2009;96(4):357-367.
67. Ushio Y, Kochi M. [Prognostic factors in malignant gliomas]. Gan To Kagaku Ryoho. 1996;23(5):643-648. (Pubitemid 26152390)
68. Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. 1996; 16(6):1413-1438; quiz 1462-1413.
69. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67(6):2729-2735. (Pubitemid 46548961)
70. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
71. Chahal M, Xu Y, Lesniak D, et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol. 2010;12(8):822-833.